Abstract 44P
Background
Oral cancer (OC) presents a high incidence of recurrences and metastasis. MicroRNA and sphingolipids alterations in plasma and tumors have been linked to many cancers. Sphingosine kinase 2 (SK2), which regulates sphingosine-1-phosphate levels, has been explored as a therapeutic target in cancer. Interestingly, our preliminary data indicate a correlation between SK2 and miRNA levels in OC. This study aimed to investigate miR-205 and miR-296, in the saliva of OC patients and the relationship between these miRNAs and SK2 in OC cells to elucidate further new diagnosis/prognosis and therapy strategies for oral cancer.
Methods
The saliva was collected and processed from 25 OC patients and 15 controls, followed by miRNA extraction. The survival rate of OC patients related to miRNA-205 and miRNA-296 levels in tumor samples was analyzed using the TCGA data. The salivary levels of the 2 miRNAs were determined by qRT-PCR. ROC curves were used to evaluate the potential of the miRNAs as biomarkers. OC cells (HN12 and HN13) without (control) and with SK2 overexpression (HN12-SK2) and SK2 knockdown (HN13-sh-SK2) were selected to evaluate the modulation of the miRNAs by qRT-PCR, as well as to perform migration and spheres assays after transfection with mimic-miRNA-205 and inhibitor for miRNA-296.
Results
The survival rate in OC patients was higher when the miR-205 was high and the miR-296 low. In our cohort, both miR-296 and miRNA-205 presented higher levels in the saliva of OC patients than in the controls. There was a positive correlation between tumor size and miR-296 levels in saliva, opposite to a negative correlation with miR-205. In vitro analysis showed that SK2 overexpression in HN12 cells (HN12-SK2) decreased the expression of miR-205 and increased miR-296, while the knockdown of SK2 in HN13 cells (HN13-sh-SK2) increased the miR-205 and decreased the miR-296. Besides, transfection of a miR-205 mimic and a miRNA-296 inhibitor in HN12/HN13 cells showed decreased cell migration and sphere formation.
Conclusions
We propose that the level of miR-205 and miR-296 in human saliva could be used for the diagnosis and prognosis of OC patients. Moreover, both miRNAs in OC cells may be regulated by sphingosine kinase 2 and explored as therapeutic targets in oral cancer.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Academic Group.
Funding
Fundação de Amparo e Pesquisa do Estado de São Paulo.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
114P - Circulating microRNAs and response to oncological and surgical therapy in patients with locally advanced gastric cancer
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
115P - BrainStorm-NSE: Serum neuron-specific enolase as a biomarker for central nervous system metastases: A prospective cohort study
Presenter: Diogo Martins-Branco
Session: Cocktail & Poster Display session
Resources:
Abstract
116P - Switching to a multigenic parallel sequencing approach: The landscape of biomarkers profiling changing between immunohistochemistry and next generation sequencing advantages and sustainability from a public hospital in Northern Italy
Presenter: Giulia Ghirardi
Session: Cocktail & Poster Display session
Resources:
Abstract
117P - Homologous recombination deficiency (HRD) by shallow whole genome sequencing (sWGS): Seamless integration in an existing NGS somatic oncology workflow
Presenter: Etienne Muller
Session: Cocktail & Poster Display session
Resources:
Abstract
118P - Molecular diagnostics of gastrointestinal stromal tumors in the era of precision oncology
Presenter: Alena Kalfusova
Session: Cocktail & Poster Display session
Resources:
Abstract
119P - De novo and histologically transformed small-cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways
Presenter: Triparna Sen
Session: Cocktail & Poster Display session
Resources:
Abstract
120P - Anti-angiogenic therapy or immunotherapy? A multicenter real-world study of patients with advanced non-small cell lung cancer with EGFR / HER2 exon 20 insertion mutations
Presenter: Tianqing Chu
Session: Cocktail & Poster Display session
Resources:
Abstract
121P - Clinical outcomes of compound EGFR mutation in non-small cell lung cancer: A national, retrospective, multicenter study
Presenter: Aurélien Brindel
Session: Cocktail & Poster Display session
Resources:
Abstract
122P - Molecular testing, treatment, and response of patients with advanced solid tumors harboring an NTRK gene fusion: Second interim results of the REALTRK registry
Presenter: Sebastian Lange
Session: Cocktail & Poster Display session
Resources:
Abstract
123P - Incidence and outcomes of anaplastic lymphoma kinase (ALK) and ROS 1 positive advanced NSCLC: A real world experience
Presenter: Stalin Chowdary Bala
Session: Cocktail & Poster Display session
Resources:
Abstract